By Sarah Smith, Editor, Today's Market Oct 9, 2020, 9:00 am EDT. GenMark Diagnostics, Inc. (NASDAQ:GNMK) Q3 2020 Earnings Conference Call October 28, 2020, 04:30 PM ET Company Participants Leigh Salvo - … As of 11:50 a.m. EDT, Nikola shares were down 7.6%. Get the latest %COMPANY_NAME% GNMK detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. $199.43m. GenMark Diagnostics Inc (GNMK) Q3 2020 Earnings Call Transcript Why Co-Diagnostics, GenMark, Luminex, and Opko Stocks Are Sinking Today GenMark Diagnostics Inc (GNMK) Q2 2020 Earnings Call Transcript View %COMPANY_NAME% GNMK investment & stock information. CMTX - Thu Mar 25, 11:40AM CDT. Management will hold a conference call to review the company's. Why Co-Diagnostics, GenMark, Luminex, and Opko Stocks Are Sinking Today Keith Speights 8/27/2020 A year of sacrifice: Why pre-pandemic photos can be painful reminders They were up 26% to $21.32 at 10:47 a.m. in New York, giving the company a … The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. The Zacks Analyst Blog Highlights: Co-Diagnostics, GenMark Diagnostics, OPKO Health and Inovio Pharmaceuticals. Shares of GenMark Diagnostics (NASDAQ: GNMK) were soaring 34.8% higher as of 11:43 a.m. EST on Thursday. Search for ticker symbols for Stocks, Mutual Funds, ETFs, Indices and Futures on Yahoo! in Top News. There are two pieces of news today … CARLSBAD, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today … Learn More. The test was developed for the qualitative detection of SARS-CoV-2 virus in nasopharyngeal swab samples for patients suspected of COVID-19 and is for use on the company’s ePlex system, which provides results in less than two hours and can process up to 96 tests per eight … February 11, 2021. According to Roche, the syndromic panel testing portfolio of GenMark Diagnostics will complement its current […] Press Release reported 10 hours ago that INVESTIGATION ALERT: Halper Sadeh LLP Investigates KSU, STAY, GNMK, NTEC, RNET; … GenMark Diagnostics News: This is the News-site for the company GenMark Diagnostics on Markets Insider. Shares in GenMark soared as much as 32% Thursday to hit a record high of $22.19. There are two pieces of news today that are related to the use of hydrogen in transportation, which Nikola is … Price to trailing twelve month operating cash flow for GNMK is currently 286.43, higher than 98.18% of US stocks with positive operating cash flow. Based on an average trading volume of 2,940,000 shares, the days-to-cover ratio is presently 1.2 days. View GenMark Diagnostics' Short Interest. How were GenMark Diagnostics' earnings last quarter? March 20, 2020—The FDA has issued an emergency use authorization for GenMark Diagnostics’ ePlex SARS-CoV-2 Test. This is why GenMark Diagnostics’ news is so important. Our growing infectious disease menu includes: Blood Culture Identification (BCID) Panels. GenMark's next quarterly update will almost certainly be even better. However, look for the healthcare stock to remain quite volatile for a while. GenMark's shares could swing up and down based on the headlines related to the coronavirus outbreak. Keith Speights has no position in any of the stocks mentioned. October 9, 2020. Management will hold a conference call to review the company's financial performance starting at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. GenMark Diagnostics Inc (NASDAQ:GNMK) stock is surging today, up 29.1% to trade at $23.88 at last check, after news of its buyout. On average, they expect GenMark Diagnostics' stock price to reach $22.01 in the next year. MotleyFool 101d. With a price/sales ratio of 10.24, GenMark Diagnostics Inc has a higher such ratio than 82.55% of stocks in our set. GNMK News Headlines. 1.6%. Second Quarter 2020 Highlights. GenMark Diagnostics (NASDAQ GNMK) News Headlines Today Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance 5 Wall Street analysts have issued 1-year price objectives for GenMark Diagnostics' shares. Their forecasts range from $18.00 to $24.05. On average, they expect GenMark Diagnostics' stock price to reach $22.01 in the next year. This suggests that the stock has a possible downside of 8.4%. The big jump came after Bloomberg reported that the diagnostics company could be acquired. GenMark Diagnostics Inc. (NASDAQ:GNMK) went down by -0.04% from its latest closing price compared to the recent 1-year high of $24.17. Their forecasts range from $18.00 to $24.05. Finance. Roche commences tender offer for all shares of GenMark Diagnostics, Inc. for $24.05 per share in cash Globe Newswire - Thu Mar 25, 11:40AM CDT. Respiratory Pathogen Panels. Roche Plans To Complete GenMark Acquisition Later … ... Why GenMark Diagnostics Stock Is Soaring Today. News of … Apr 22, 2021. Leigh Salvo - Investor Relations . Many brokerage firms have already submitted their reports for GNMK stocks, with Needham repeating the rating for This suggests that the stock has a possible downside of 8.4%. 3 months ago - Schaeffers Research SHAREHOLDER ALERT: WeissLaw LLP Investigates GenMark Diagnostics, Inc. SAN DIEGO, May 28, 2010 (BUSINESS WIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a provider of automated, multiplex molecular diagnostic testing systems, announced today that its initial public offering of 4,600,000 shares of its common stock has been priced at $6.00 per share. April 22, 2021 - 1:00 am. Today's rally is a response to the news that GenMark submitted its ePlex SARS-CoV-2 Test to the Food and Drug Administration (FDA) for an Emergency Use Authorization (EUA). GenMark Diagnostics is a molecular diagnostics company focused on developing and commercializing its sensor detection technology. GenMark Diagnostics jumped 21% on the stock market today to close at 18.86, extending into profit-taking territory after hitting a buy point … In fact, with such an urgent need, demand is strong. The test provides results in less than two hours for more than 20 viruses and bacteria that cause respiratory infections, including COVID-19, flu, bronchitis, and the common cold. View analysts' price targets for GenMark Diagnostics or view top-rated stocks among Wall Street analysts. GenMark Diagnostics offers molecular diagnostic tests that can detect multiple pathogens from a single patient sample. GenMark Announces Pricing of Its Initial Public Offering. CARLSBAD, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended June 30, 2020. Today we take an in-depth look at medical diagnostic concern GenMark Diagnostics. Total revenue of $40.1 million, an increase of 118% over the second quarter of 2019 15.6 KB. Oct. 9, 2020— GenMark Diagnostics received FDA emergency use authorization for its ePlex Respiratory Pathogen Panel 2. Why GenMark Diagnostics Stock Is Falling Today Investors appear to be taking profits after the stock soared earlier this week on news that the … Find the latest GenMark Diagnostics, Inc. (GNMK) stock quote, history, news and other vital information to help you with your stock trading and investing. The Company’s electrochemical technology enables the detection of up to 72 distinct biomarkers in a single sample. A high-level overview of GenMark Diagnostics, Inc. (GNMK) stock. Shares of GenMark Diagnostics ( NASDAQ:GNMK) were soaring 34.8% higher as of 11:43 a.m. EST on Thursday. GenMark Diagnostics, Inc. (NASDAQ:GNMK) Q4 2019 Results Conference Call March 2, 2020 4:30 PM ET Company Participants. Basel, 22 April 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and GenMark Diagnostics, Inc. today announced that Roche's wholly owned subsidiary Geronimo Acquisition Corp. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of GenMark Diagnostics, Inc. … GenMark Diagnostics (NASDAQ: GNMK) is looking to leverage new interest — and new necessity — when it comes to the novel coronavirus.
Lake Placid Monarch Ice Skates,
Kirin Light Beer Carbs,
Responsive 3d Slider Codepen,
Arc'teryx Ca 34438 Gore-tex,
Best Tactics Fm20 Mobile,
Todoroki Blue Fire Fanfiction,